Competitor Analysis: Enzyme Replacement Therapies

Publisher: La Merie Publishing
Pages: 74
Format: PDF
Product Line:
Competitor Analysis
Product Code: LMCA0032
Release Date: January of 2013

300.00 €
Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
License:
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Competitor Analysis: Enzyme Replacement & Enhancement Therapies (ERT)

 

Product description

The Competitive Intelligence Report Enzyme Replacement & Enhancement   Therapies (ERT) as of January 2013 provides a competitor analysis in   the development pipeline of novel enzyme replacement therapies and of   enzyme enhancement therapies to treat human genetic diseases/lysosomal   storage diseases and exocrine pancreatic insufficiency due to cystic   fibrosis, pancreatitis and other causes.

 

Purchase of the downloadable pdf report includes a 6-month online   access to the data of the report and any updates since the publication   date. Credentials to access the database will be sent by e-mail and   allow online work with the project data to print or export an individual   report.

 

The report includes a compilation of current active projects in   research and development of novel enzyme replacement & enhancement   therapy products and an overview of approved products. In addition, the   report lists company-specific product portfolios and R&D pipelines   of enzyme replacement and enhancement therapies. Competitor projects are   listed in a tabular format providing Information on:

  • Drug Codes,
  • Target / Mechanism of Action, 
  • Class of Compound, 
  • Company, 
  • Product Category, 
  • Indication, 
  • R&D Stage and 
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise   information about the pipeline of R&D projects for targets,   diseases, technologies and companies at low prices. The information is   provided in a tabular format and fully referenced.

Enzyme Replacement & Enhancement Therapies (ERT)

Table of Contents

  • Gaucher Disease
  • Fabry Disease
  • Pompé Disease
  • Hunter Disease (MPS II)
  • Niemann Pick Diseases
  • Mucopolysaccharidosis I (MPS I)
  • San Filippo Syndrome (MPS IIIA)
  • Morquio Syndrome (MPS IVA)
  • Mucopolysaccharidosis VI (MPS VI)
  • Tay-Sachs Disease
  • Chronic Deficiency of Adenosine Deaminase
  • Phenylketonuria / Hyperphenylalaninemia
  • Other Enzyme Replacement Therapies
  • Exocrine Pancreatic Insufficiency: Porcine-Derived ERT
  • Exocrine Pancreatic Insufficiency: Recombinant ERT
  • Others

 

 



The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top